Shepherd Financial Partners LLC Has $1.56 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Shepherd Financial Partners LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,756 shares of the company’s stock after selling 335 shares during the quarter. Shepherd Financial Partners LLC’s holdings in Johnson & Johnson were worth $1,556,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Golden State Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $608,000. Centerline Wealth Advisors LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at $213,000. Live Oak Private Wealth LLC lifted its stake in Johnson & Johnson by 1.8% during the 4th quarter. Live Oak Private Wealth LLC now owns 6,743 shares of the company’s stock valued at $975,000 after acquiring an additional 116 shares in the last quarter. Global X Japan Co. Ltd. boosted its holdings in Johnson & Johnson by 17.7% during the 4th quarter. Global X Japan Co. Ltd. now owns 3,178 shares of the company’s stock worth $460,000 after acquiring an additional 478 shares during the last quarter. Finally, Prairie Wealth Advisors Inc. raised its holdings in shares of Johnson & Johnson by 2.8% in the fourth quarter. Prairie Wealth Advisors Inc. now owns 3,061 shares of the company’s stock valued at $443,000 after purchasing an additional 84 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.7 %

JNJ stock opened at $154.22 on Tuesday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The firm has a market capitalization of $371.31 billion, a PE ratio of 23.19, a PEG ratio of 2.46 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock has a 50-day simple moving average of $147.42 and a two-hundred day simple moving average of $156.08.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the firm earned $2.29 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.22%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent analyst reports. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Raymond James decreased their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Leerink Partners reduced their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.